Filing Flows › BioXcel Therapeutics (BTAIQ) › Q2 2026 › vs Q1 2026
BioXcel Therapeutics (BTAIQ) Q2 2026 vs Q1 2026 (quarter over quarter)
BioXcel Therapeutics's revenue fell $24K (-12%) from $206K in Q1 2026 to $182K in Q2 2026.
BioXcel Therapeutics, Q2 2026: revenue $182K (+52% year over year), net loss $14.7M, operating cash flow −$6.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $182K | $206K | −$24K | -12% |
| Net loss | $14.7M | $12.7M | $2.0M | +16% |
| Costs & expenses | $14.9M | $12.9M | $2.0M | +15% |
| Operating costs | $10.4M | $10.4M | −$54K | -0.5% |
| Interest & other, net | $4.5M | $2.5M | $2.1M | +83% |
| Cost of revenue | $22K | $283K | −$261K | -92% |
| Research & development | $3.2M | $3.0M | $209K | +7% |
| SG&A | $7.2M | $7.2M | −$2K | 0% |
| Operating cash sources | $14.7M | $12.7M | $2.0M | +16% |
| Depreciation | $18K | $58K | −$40K | -69% |
| Share-based compensation | $358K | $435K | −$77K | -18% |
| Working capital & other | $8.2M | $389K | $7.8M | 21× |
| Cash used in operations | $6.1M | $11.8M | −$5.7M | -48% |
| Net loss absorbed | $14.7M | $12.7M | $2.0M | +16% |
Questions
How much did BioXcel Therapeutics's revenue grow quarter over quarter in Q2 2026?
BioXcel Therapeutics's revenue fell $24K (-12%) from $206K in Q1 2026 to $182K in Q2 2026.